Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India’s pharmaceutical sector stands at a pivotal inflection point
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
